Document is current
Any future updates will be listed below
-
Authors
Swaminathan, Aparna C
McFatrich, Molly
Mkumba, Laura
Wright, Lauren
Redlich, Carrie A
Snyder, Laurie D
Reeve, Bryce B
Patel, Divya
Gulati, Mridu
- License Information
-
More Information
Article History
Received: 25 June 2024
Accepted: 2 October 2024
First Online: 15 October 2024
Declarations
:
: This study was approved by the Duke Institutional Review Board (Pro00110042) and was carried out in compliance with the principles of the Declaration of Helsinki and the Harmonised Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonisation. All patients provided informed consent.
: Not applicable.
: ACS, LDS, and BBR are faculty members of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc. to run the IPF-PRO/ILD-PRO Registry. MM, LM, LW are employees of the Duke University School of Medicine, which received funding support from Boehringer Ingelheim Pharmaceuticals, Inc, for its contribution to this study. ACS has received fees as an advisory committee member for United Therapeutics. CR has no disclosures. DP is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. MG has received fees and non-financial support from the France Foundation; grants and other support from Boehringer Ingelheim and the Pulmonary Fibrosis Foundation; and fees from Genentech.
